Therapeutic blockade of IL-1β in PWH reduced the HIV reservoir via mechanisms of enhanced CD8 and CD4 effector function and reversal of monocyte dysfunction
Sharma, A. A., Dropathi, M., Sadek, N., Li, D., Dwivedi, A. K., Siegel, D., Rutishauser, R., Deeks, S., et al.
hiv aids
Quick verdict
Claims canakinumab reduces HIV reservoir via T-cell effector gains and monocyte reset; an n=10 uncontrolled pre-post omics study, suggestive but not proven.
Summary
This preprint examines whether IL-1β blockade with canakinumab affects the HIV reservoir, leveraging a single-arm CANTOS substudy in which 10 ART-suppressed people with HIV received one 150 mg infusion. Whole-blood RNA-seq at Weeks 0 and 8 (n=8 after outlier removal) identified 2,617 induced and 2,660 repressed genes; the derived Cana_Up (94 genes) and Cana_Down (142 genes) signatures correlated negatively and positively, respectively, with HIV DNA fold-change. Five of eight participants were classified responders. Cana_Up genes mapped to CD4/CD8 T cells and cell-cycle/antigen-presentation pathways; Cana_Down genes mapped to CD14+ monocytes and NF-κB/EZH2/JARID2 programs. Flow cytometry after Gag stimulation found responder-enriched CD8/CD4 effector clusters whose frequencies correlated negatively with reservoir change (e.g., r=-0.955, n=8). Associations were validated in 21 independent SCOPE participants, where plasma IL-1β correlated with the TILDA reservoir measure (rho=0.69). Limitations: no placebo arm, very small sample, post hoc responder definitions, dozens of uncorrected n=8 correlations using a normal approximation, internal inconsistencies (5/8 vs 6/10 responders; figure cross-references), and data/code not yet deposited. The mechanistic narrative is coherent and hypothesis-generating, but causal attribution to canakinumab remains unproven.
Review complete
Assessment at a glance
5
risk flags identified
● high 2
● medium 3
● low 0
4 strengths · 5 weaknesses · 5 author questions
AI text signal = Binoculars zero-shot detector score over 20 sampled passages (Fast-DetectGPT co-reported) — absence does not prove human authorship, and a flag does not imply misconduct.
Levels reflect verification complexity — not a quality score. Evolve never rates your paper.
Key claims under review
- Canakinumab-induced whole-blood signatures Cana_Up (94 genes) and Cana_Down (142 genes) are respectively negatively (NES=-2.178, q=2.26e-6) and positively (NES=2.53, q=5.63e-14) associated with HIV reservoir fold-change after treatment.
- Participants whose reservoir declined show enhanced HIV Gag-specific CD4 and CD8 effector clusters (e.g., Clusters 19 and 20), whose frequencies negatively correlate with reservoir fold-change.
- CD14+ classical monocytes are the dominant source of plasma IL-1β and express canakinumab-suppressed inflammatory/epigenetic programs (NF-κB, RELA, EZH2, JARID2), while CD16+ non-classical monocytes express antigen cross-presentation and cell-cycle programs.
- Blood Th17 cells and gut tissue-resident HIV reservoir cells (Trm BACH2-high subsets from Wei et al.) express the pathways that canakinumab suppresses, implying dual blood/gut targetability of a single IL-1β-targeting agent.
Strengths
Multi-omic triangulation on treated specimens
Bulk whole-blood RNA-seq (Wk0/Wk8), scRNA-seq (n=5, Wk0/Wk4), 27-marker flow cytometry with Rphenograph, a 23-plex MSD cytokine panel, and reanalysis of the public Wei et al. gut dataset converge on a cell-type-resolved mechanism (Th17/Trm express Cana_Down; CD14+ vs CD16+ monocyte dichotomy in Fig. 4).
Independent-cohort validation of the core signature
Cana_Up leading-edge genes are negatively associated with both TILDA and plasma IL-1β in 21 SCOPE participants (Fig. 1G-H), where IL-1β–TILDA correlate at rho=0.69, p=0.0008; the study also maps their published anti-PD1 CD8 effector signature onto this data (adj. p=0.00096), supporting generalizability.
Honest negative control built into the design
Therapeutic framing grounded in prior human data
Weaknesses
Uncontrolled single-arm design cannot support the causal title
Fragile small-sample statistics
Internal inconsistencies undermine confidence
Reservoir endpoints are limited and temporally mismatched
Nothing verifiable is deposited
Full Review Report
$1.99 · one-timeUnlock the complete preliminary analysis Evolve produced for this paper.
Report preview
Scope & Claims
This medRxiv preprint (posted 2026-09-17, not certified by peer review) presents mechanistic analyses of a previously published single-arm substudy of CANTOS in which ten ART-suppressed people with HIV (PWH) with cardiovascular risk factors received a single 150 mg canakinumab (anti–IL-1β) infusion. The authors claim that: (1) canakinumab-induced transcriptional signatures — Cana_Up (94 genes) and Cana_Down (142 genes) — track with HIV reservoir reduction (GSEA against HIV DNA fold-change: Cana_Up NES=-2.178, q=2.26e-6; Cana_Down NES=2.53, q=5.63e-14); (2) responders show enhanced HIV Gag-specific CD4 and CD8 effector responses; (3) CD14+ classical monocytes are the dominant IL-1β source and carry the suppressed NF-κB/EZH2/JARID2 programs, while CD16+ monocytes gain antigen cross-presentation programs; and (4) blood Th17 cells and gut Trm reservoir cells express the targeted pathways. The title asserts causation; the abstract more cautiously says the response *is associated to* the signatures.
The remaining sections cover Methodology Assessment, Statistical Evidence, Results & Reproducibility, Limitations & Risks, and Verdict & Recommendations.
- All 4 strengths & 5 weaknesses, analyzed in detail
- 5 risk flags with severity, section & reviewer questions
- Methods & statistical evidence assessment
- 5 questions a peer reviewer would ask
- Full six-dimension evaluation report & recommendations
One-time purchase · this paper only
One-time purchase, this paper only. AI-generated preliminary analysis — not peer review.
Frequently asked questions
Does canakinumab cure HIV or reduce the HIV reservoir?
There is no evidence of a cure. In this small, uncontrolled study of 10 treated people (8 analyzed), 5-6 showed reduced blood HIV DNA after a single dose, and reservoir reduction coincided with stronger HIV-specific T cell responses. Without a placebo group, whether canakinumab caused the decline is unproven; the paper is a preprint not yet peer reviewed.
What is the HIV reservoir?
It is the pool of cells — mainly resting CD4+ T cells, including gut tissue-resident memory cells — that carry latent HIV DNA despite antiretroviral therapy. The reservoir is why therapy must be taken for life, and shrinking it is a central goal of HIV cure research.
What is canakinumab and why was it tested in people with HIV?
Canakinumab (Ilaris) is an FDA-approved monoclonal antibody that neutralizes IL-1β, an inflammatory cytokine. It reduced cardiovascular events in the large CANTOS trial, and a prior substudy showed it lowered arterial and bone-marrow inflammation in people with HIV — making it a candidate to address both cardiovascular risk and HIV-related inflammation in one agent.
How reliable are the results of this study?
The group is reputable and the multi-omic design with an independent validation cohort is a strength, but the sample is tiny (8 analyzed), there is no control arm, several statistical choices (small-n correlations, no multiple-testing correction) and internal inconsistencies (e.g., conflicting responder counts) need correction, and the underlying data are not yet publicly deposited. Treat the findings as hypothesis-generating.
About this review
This is an AI-generated preliminary review by Evolve.Pub, produced from the openly available text of the paper. It is not peer review and does not represent the authors' views. The canonical record of the paper is at the publisher link above.
- All figures and Extended Data were unavailable as images; judgments about visual evidence rest on captions and in-text statistics only.
- Text extraction truncated several sections (part of the cytokine-signature paragraph, part of the monocyte section, scRNA methods, and any funding/conflict-of-interest statements), so some design details could not be verified.
- Supplemental Table 1 (pathway statistics and leading-edge gene lists) was not accessible; signature membership claims could not be spot-checked.
- The responder discrepancy (5/8 vs 6/10) and figure cross-reference errors are taken from the extracted text; camera-ready figures may differ.
Go deeper on this paper
Wrote a paper? Stress-test it before reviewers do.
Upload your manuscript for the same structured scrutiny — reasoning, statistics, evidence, figures, and reproducibility.